Does esaxerenone added to existing renin-angiotensin system inhibitor therapy improve albuminuria in patients with type 2 diabetes and microalbuminuria?
Esaxerenone added to RAS inhibitors improves albuminuria outcomes in patients with type 2 diabetes and microalbuminuria.
Adding esaxerenone to existing renin-angiotensin system inhibitor therapy in patients with type 2 diabetes and microalbuminuria increased the likelihood of albuminuria returning to normal levels, and reduced progression of albuminuria to higher levels.
Ito et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: